Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 210

1.

[French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].

Rozet F, Hennequin C, Mongiat-Artus P, Beuzeboc P, Beauval JB, Cormier L, Fromont-Hankard G, Ouzzane A, Ploussard G, Renard-Penna R, Méjean A.

Prog Urol. 2018 May;28(6):303-306. doi: 10.1016/j.purol.2018.03.006. Epub 2018 Apr 19. French. No abstract available.

PMID:
29680190
2.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S.

Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7.

PMID:
29636272
3.

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.

Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.

PMID:
29074061
4.

Radium 223 dichloride for prostate cancer treatment.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N.

Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Review.

5.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2017 Mar 7. pii: S2405-4569(17)30065-2. doi: 10.1016/j.euf.2017.02.017. [Epub ahead of print] Review.

PMID:
28753865
6.

Long-Term Results of a Highly Performing Conformal Electron Therapy Technique for Chest Wall Irradiation After Mastectomy.

Grellier Adedjouma N, Chevrier M, Fourquet A, Costa E, Xu H, Berger F, Campana F, Laki F, Beuzeboc P, Lefeuvre D, Fournier-Bidoz N, Kirova YM.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):206-214. doi: 10.1016/j.ijrobp.2017.01.205. Epub 2017 Jan 27.

PMID:
28586961
7.

First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.

Dieras V, Pop S, Berger F, Dujaric ME, Beuzeboc P, Escalup L, Bidard FC, Cottu PH, LE Tourneau C, Piperno-Neumann S, Laurence V, Robain M, Asselain B, Pierga JY.

Anticancer Res. 2017 Mar;37(3):1403-1407.

PMID:
28314310
8.

Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer.

Geraud A, Xu HP, Beuzeboc P, Kirova YM.

J Neurooncol. 2017 Jan;131(1):69-72. doi: 10.1007/s11060-016-2265-z. Epub 2016 Dec 19.

PMID:
27995546
9.

[CCAFU french national guidelines 2016-2018 on prostate cancer].

Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Lebret T, Rebillard X, Soulié M, Renard-Penna R, Méjean A.

Prog Urol. 2016 Nov;27 Suppl 1:S95-S143. doi: 10.1016/S1166-7087(16)30705-9. Review. French.

PMID:
27846936
10.

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.

Gravis G, Audenet F, Irani J, Timsit MO, Barthelemy P, Beuzeboc P, Fléchon A, Linassier C, Oudard S, Rebillard X, Richaud P, Rouprêt M, Thiery Vuillemin A, Vincendeau S, Albiges L, Rozet F.

Cancer Treat Rev. 2017 Apr;55:211-217. doi: 10.1016/j.ctrv.2016.09.008. Epub 2016 Sep 10. Review.

11.

Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.

Pouessel D, Bastuji-Garin S, Houédé N, Vordos D, Loriot Y, Chevreau C, Sevin E, Beuzeboc P, Taille A, Le Thuaut A, Allory Y, Culine S.

Clin Genitourin Cancer. 2017 Feb;15(1):e45-e52. doi: 10.1016/j.clgc.2016.07.012. Epub 2016 Jul 21.

PMID:
27554584
12.

Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.

Géraud A, Xu HP, Beuzeboc P, Kirova YM.

Cancer Radiother. 2016 Jun;20(4):312-3. doi: 10.1016/j.canrad.2016.03.010. Epub 2016 Jun 21. No abstract available.

PMID:
27342941
13.

Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment.

Pouessel D, Neuzillet Y, Mertens LS, van der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A, Maille P, Soyeux P, Moktefi A, Semprez F, Vordos D, de la Taille A, Hurst CD, Tomlinson DC, Harnden P, Bostrom PJ, Mirtti T, Horenblas S, Loriot Y, Houédé N, Chevreau C, Beuzeboc P, Shariat SF, Sagalowsky AI, Ashfaq R, Burger M, Jewett MA, Zlotta AR, Broeks A, Bapat B, Knowles MA, Lotan Y, van der Kwast TH, Culine S, Allory Y, van Rhijn BW.

Ann Oncol. 2016 Jul;27(7):1311-6. doi: 10.1093/annonc/mdw170. Epub 2016 Apr 18.

14.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG.

Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.

PMID:
26610858
15.

[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].

Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, Gligorov J.

Bull Cancer. 2015 Nov;102(11):906-14. French.

PMID:
26603517
16.

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients.

Roubaud G, Brouste V, Beuzeboc P, Fléchon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houédé N.

J Negat Results Biomed. 2015 Nov 10;14:18. doi: 10.1186/s12952-015-0037-5.

17.

Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study.

Chocteau-Bouju D, Chakiba C, Mignot L, Madranges N, Pierga JY, Beuzeboc P, Quenel-Tueux N, Dieras V, Bonnefoi H, Debled M, Cottu P.

Breast. 2015 Dec;24(6):718-22. doi: 10.1016/j.breast.2015.09.002. Epub 2015 Sep 19.

PMID:
26387602
18.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
19.

[How to manage patients with CRPC?].

Beuzeboc P, Massard C.

Bull Cancer. 2015 Jun;102(6):509-15. doi: 10.1016/j.bulcan.2015.04.015. Epub 2015 May 28. Review. French.

PMID:
26028494
20.

The androgen receptor for the radiation oncologist.

Quero L, Rozet F, Beuzeboc P, Hennequin C.

Cancer Radiother. 2015 May;19(3):220-7. doi: 10.1016/j.canrad.2015.02.008. Epub 2015 Apr 23. Review.

PMID:
25921704
21.

Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA.

Spano JP, Beuzeboc P, Coeffic D, Arnould L, Lortholary A, Andre F, Ferrero JM.

Breast. 2015 Aug;24(4):376-83. doi: 10.1016/j.breast.2015.02.035. Epub 2015 Apr 23.

PMID:
25913287
22.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D.

BMC Cancer. 2015 Apr 4;15:222. doi: 10.1186/s12885-015-1257-2.

23.

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.

de la Rochefordiere A, Kamal M, Floquet A, Thomas L, Petrow P, Petit T, Pop M, Fabbro M, Kerr C, Joly F, Sevin E, Maillard S, Curé H, Weber B, Brunaud C, Minsat M, Gonzague L, Berton-Rigaud D, Aumont M, Gladieff L, Peignaux K, Bernard V, Leroy Q, Bieche I, Margogne A, Nadan A, Fourchotte V, Diallo A, Asselain B, Plancher C, Armanet S, Beuzeboc P, Scholl SM.

Clin Cancer Res. 2015 Jun 1;21(11):2530-7. doi: 10.1158/1078-0432.CCR-14-2368. Epub 2015 Feb 27.

24.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.

Houédé N, Dupuy L, Fléchon A, Beuzeboc P, Gravis G, Laguerre B, Théodore C, Culine S, Filleron T, Chevreau C.

BJU Int. 2016 Mar;117(3):444-9. doi: 10.1111/bju.13054. Epub 2015 Apr 27.

25.

[Imagery of treated prostate cancer].

Renard-Penna R, Michaud L, Cormier L, Bastide C, Beuzeboc P, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Rozet F, Richaud P, Salomon L, Soulié M; membres du Comité de cancérologie de l’AFU.

Prog Urol. 2015 Mar;25(3):128-37. doi: 10.1016/j.purol.2014.12.002. Epub 2015 Jan 13. Review. French.

PMID:
25595615
26.
27.

Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.

Oudard S, Culine S, Vano Y, Goldwasser F, Théodore C, Nguyen T, Voog E, Banu E, Vieillefond A, Priou F, Deplanque G, Gravis G, Ravaud A, Vannetzel JM, Machiels JP, Muracciole X, Pichon MF, Bay JO, Elaidi R, Teghom C, Radvanyi F, Beuzeboc P.

Eur J Cancer. 2015 Jan;51(1):45-54. doi: 10.1016/j.ejca.2014.10.009. Epub 2014 Nov 15.

PMID:
25459391
28.

[Management of low-risk prostate cancer].

Rozet F, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Renard-Penna R, Richaud P, Salomon L, Soulié M; Les membres du comité de cancérologie de l’AFU.

Prog Urol. 2015 Jan;25(1):1-10. doi: 10.1016/j.purol.2014.10.007. Epub 2014 Nov 20. Review. French.

PMID:
25454776
29.

Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.

Jacob J, Belin L, Pierga JY, Gobillion A, Vincent-Salomon A, Dendale R, Beuzeboc P, Campana F, Fourquet A, Kirova YM.

Breast Cancer Res Treat. 2014 Nov;148(2):345-53. doi: 10.1007/s10549-014-3166-5. Epub 2014 Oct 16.

PMID:
25318926
30.

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.

Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S.

Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30.

PMID:
25277272
31.

[Concurrent association of reirradiation therapy with everolimus for lymph node metastasis of gastroesophageal junction cancer: a case report].

Pernin V, Beuzeboc P, Peurien D, Louvet C, Kirova Y.

Cancer Radiother. 2014 Nov;18(7):681-4. doi: 10.1016/j.canrad.2014.04.007. Epub 2014 Jun 26. French.

PMID:
24981410
32.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
33.

[Prostate cancer surgical margin: review by the CCAFU (Oncology Committee of the French Association of Urology)].

Cormier L, Bastide C, Beuzeboc P, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Richaud P, Rozet F, Soulié M, Salomon L; les membres du sous-comité « prostate » du CCAFU.

Prog Urol. 2014 May;24(6):334-45. doi: 10.1016/j.purol.2013.11.006. Epub 2013 Dec 9. Review. French.

PMID:
24821555
34.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
35.

[Management of enzalutamide, a new hormonal therapy].

Beuzeboc P, Benderra MA, de La Motte Rouge T.

Bull Cancer. 2014 Jan 1;101(1):107-12. doi: 10.1684/bdc.2013.1880. French.

PMID:
24491670
36.

[CCAFU Recommendations 2013: Prostate cancer].

Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinié V, Ravery V, Rebillard X, Richaud P, Villers A, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S69-101. doi: 10.1016/S1166-7087(13)70048-4. French.

PMID:
24485295
37.

Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).

Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K.

Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11.

PMID:
24424105
38.

Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives.

Beuzeboc P, Scholl S.

J Clin Med. 2014 May 9;3(2):521-36. doi: 10.3390/jcm3020521. Review.

39.

[The non-hormonal treatment of metastatic prostate cancer].

Mongiat-Artus P, Brenot-Rossi I, Beuzeboc P, Bruyère F, Karsenty G, Guy L, Bastide C.

Prog Urol. 2013 Nov;23(15):1258-64. doi: 10.1016/j.purol.2013.08.322. Epub 2013 Oct 2. Review. French.

PMID:
24183084
40.

A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study.

Fizazi K, Delva R, Caty A, Chevreau C, Kerbrat P, Rolland F, Priou F, Geoffrois L, Rixe O, Beuzeboc P, Malhaire JP, Culine S, Aubelle MS, Laplanche A.

Eur Urol. 2014 Feb;65(2):381-6. doi: 10.1016/j.eururo.2013.09.004. Epub 2013 Sep 13.

PMID:
24094847
41.

[Prostate brachytherapy: indications and outcomes].

Hennequin C, Cormier L, Richaud P, Bastide C, Beuzeboc P, Fromont G, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Soulié M, Salomon L; Les membres du CC-AFU.

Prog Urol. 2013 May;23(6):378-85. doi: 10.1016/j.purol.2012.12.006. Epub 2013 Jan 29. Review. French.

PMID:
23628094
42.

[Prospective monocentric study of the toxicity and the efficacy of concurrent trastuzumab and radiotherapy].

Jacob J, Belin L, Gobillion A, Daveau-Bergerault C, Dendale R, Beuzeboc P, Campana F, Bollet MA, Fourquet A, Kirova YM.

Cancer Radiother. 2013 Jun;17(3):183-90. doi: 10.1016/j.canrad.2012.12.006. Epub 2013 Mar 15. French.

PMID:
23499212
43.

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M.

Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8.

PMID:
23306100
44.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
45.

[5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology].

Eschwège P, Gaschignard N, Ploussard G, Peyromaure M, Bastide C, Cormier L, Mongiat-Artus P, Rozet F, Fromont G, Hennequin C, Renard-Penna R, Beuzeboc P, Richaud P, Soulié M, Salomon L; les membres du CCAFU.

Prog Urol. 2012 Sep;22(10):555-60. doi: 10.1016/j.purol.2012.04.007. Epub 2012 May 14. Review. French.

PMID:
22920332
46.

[Lymphadenectomy and prostate cancer: a statement of the committee of cancerology of the French Association of Urology].

Salomon L, Peyromaure M, Fromont G, Rozet F, Eiss D, Bastide C, Beuzeboc P, Gachignard N, Cormier L, Hennequin C, Mongiat-Artus P, Soulié M; sous-comité prostate du CCAFU; Committee of cancerology of the French Association of Urology.

Prog Urol. 2012 Jul;22(9):510-9. doi: 10.1016/j.purol.2012.04.005. Epub 2012 May 17. Review. French.

PMID:
22732642
47.

[Management of metastatic castration-resistant prostate cancer following docetaxel].

Beuzeboc P, Ropert S, Goldwasser F, Zerbib M.

Bull Cancer. 2012 Jul;99 Suppl 1:S66-72. doi: 10.1684/bdc.2012.1560. Review. French.

PMID:
22516457
48.

[Chemotherapy in perioperative setting for infiltrative bladder cancer].

Houédé N, Beuzeboc P, Culine S, Soulié M, Pfister C; Groupe vessie du Comité de cancérologie de l’Association française d’urologie.

Prog Urol. 2012 Mar;22(3):139-45. doi: 10.1016/j.purol.2011.09.010. Epub 2011 Oct 28. Review. French.

PMID:
22364623
49.

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.

Bidard FC, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Cottu P, Beuzeboc P, Rolland E, Mathiot C, Pierga JY.

Breast Cancer Res. 2012 Feb 13;14(1):R29.

50.

A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.

Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S.

Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24.

PMID:
22119204

Supplemental Content

Loading ...
Support Center